CT275 / 15 - Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors

B Carneiro, Rachel E Sanborn, See full list of authors in comments

Research output: Other contribution

Fingerprint

Dive into the research topics of 'CT275 / 15 - Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science